PSMD2 Antibody [B5P6] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat, Monkey

Usage Information

Dilution
WB1:1000

Application
WB

Reactivity
Human, Mouse, Rat, Monkey

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
97 kDa

Positive Control	PC-3 cells; RPMI 8226 cells; OVCAR3 cells; HCT 116 cells; LOX-IMVI cells; Hs578T cells; 786-0 cells; NCI-H23 cells; Hepa 1-6 cells; A-10 cells; COS-7 cells
Negative Control

Datasheet & SDS

Biological Description

Specificity
PSMD2 Antibody [B5P6] detects endogenous levels of total PSMD2 protein.

Clone
B5P6

Synonym(s)
26S proteasome non-ATPase regulatory subunit 2; 26S proteasome regulatory subunit RPN1; 26S proteasome subunit p97; Protein 55.11; PSMD2; TRAP2

Background
PSMD2 (also known as Rpn1) is a non-ATPase subunit of the 19S regulatory particle (RP) lid within the 26S proteasome, playing a central scaffolding and ubiquitin receptor docking role essential for ATP- and ubiquitin-dependent degradation of misfolded proteins and regulatory factors, thereby ensuring cellular proteostasis. This large (~950 amino acids) protein contains PCI (proteasome-COP9 initiation) and 26S proteasome non-ATPase regulatory subunit domains, which together form a conformationally flexible scaffold at the periphery of the RP. PSMD2 features multiple PCI/MPN-binding surfaces that facilitate docking of ubiquitin shuttle proteins (such as Rad23 and Dsk2 via their UBL domains) and ubiquitin receptors (Rpn10 and Rpn13), effectively positioning ubiquitinated substrates for handoff to the ATPase base ring. PSMD2 coordinates the recognition of ubiquitin chains and their remodeling by lid-associated deubiquitinases (DUBs) like Rpn11, which, in concert with the AAA-ATPase ring (Rpt1-6), unfolds protein substrates and directs them through the gated 20S core β-subunits for proteolysis. As a result, the 26S proteasome processes approximately 70% of intracellular proteins, including key regulators of the cell cycle, apoptosis, and MHC class I antigen presentation. PSMD2 directly interacts with the intracellular domain of the TNF receptor, thereby linking proteasomal activity to the TNF/NF-κB signaling axis and contributing to immune regulation and inflammation. PSMD2 overexpression is associated with poor outcomes in lung adenocarcinoma and hepatocellular carcinoma, where it drives immune checkpoint modulation and resistance to therapy; conversely, PSMD2 inhibition selectively impairs proteasome chymotrypsin-like activity, inducing apoptosis in tumor cells while largely sparing healthy tissue.

Background

PSMD2 (also known as Rpn1) is a non-ATPase subunit of the 19S regulatory particle (RP) lid within the 26S proteasome, playing a central scaffolding and ubiquitin receptor docking role essential for ATP- and ubiquitin-dependent degradation of misfolded proteins and regulatory factors, thereby ensuring cellular proteostasis. This large (~950 amino acids) protein contains PCI (proteasome-COP9 initiation) and 26S proteasome non-ATPase regulatory subunit domains, which together form a conformationally flexible scaffold at the periphery of the RP. PSMD2 features multiple PCI/MPN-binding surfaces that facilitate docking of ubiquitin shuttle proteins (such as Rad23 and Dsk2 via their UBL domains) and ubiquitin receptors (Rpn10 and Rpn13), effectively positioning ubiquitinated substrates for handoff to the ATPase base ring. PSMD2 coordinates the recognition of ubiquitin chains and their remodeling by lid-associated deubiquitinases (DUBs) like Rpn11, which, in concert with the AAA-ATPase ring (Rpt1-6), unfolds protein substrates and directs them through the gated 20S core β-subunits for proteolysis. As a result, the 26S proteasome processes approximately 70% of intracellular proteins, including key regulators of the cell cycle, apoptosis, and MHC class I antigen presentation. PSMD2 directly interacts with the intracellular domain of the TNF receptor, thereby linking proteasomal activity to the TNF/NF-κB signaling axis and contributing to immune regulation and inflammation. PSMD2 overexpression is associated with poor outcomes in lung adenocarcinoma and hepatocellular carcinoma, where it drives immune checkpoint modulation and resistance to therapy; conversely, PSMD2 inhibition selectively impairs proteasome chymotrypsin-like activity, inducing apoptosis in tumor cells while largely sparing healthy tissue.

References
https://pubmed.ncbi.nlm.nih.gov/27396824/ https://pubmed.ncbi.nlm.nih.gov/31843888/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%